Prenatal Dexamethasone for Congenital Adrenal HyperplasiaReport as inadecuate

Prenatal Dexamethasone for Congenital Adrenal Hyperplasia - Download this document for free, or read online. Document in PDF available to download.

Journal of Bioethical Inquiry

, Volume 9, Issue 3, pp 277–294

An Ethics Canary in the Modern Medical MineFirst Online: 31 July 2012Received: 11 April 2012Accepted: 14 May 2012


Following extensive examination of published and unpublished materials, we provide a history of the use of dexamethasone in pregnant women at risk of carrying a female fetus affected by congenital adrenal hyperplasia CAH. This intervention has been aimed at preventing development of ambiguous genitalia, the urogenital sinus, tomboyism, and lesbianism. We map out ethical problems in this history, including: misleading promotion to physicians and CAH-affected families; de facto experimentation without the necessary protections of approved research; troubling parallels to the history of prenatal use of diethylstilbestrol DES; and the use of medicine and public monies to attempt prevention of benign behavioral sex variations. Critical attention is directed at recent investigations by the U.S. Food and Drug Administration FDA and Office of Human Research Protections OHRP; we argue that the weak and unsupported conclusions of these investigations indicate major gaps in the systems meant to protect subjects of high-risk medical research.

KeywordsCongenital adrenal hyperplasia Dexamethasone Medical ethics Gender identity Sexual orientation Human subjects research  Download fulltext PDF

Author: Alice Dreger - Ellen K. Feder - Anne Tamar-Mattis



Related documents